News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
News Kymera signs $750m cancer deal with Gilead as Sanofi opts in Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
News ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).
News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News UK's HIV response is 'failing women' Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing and care, says a new campaign.
News NHS trust rolls out digital health tool for kidney disease An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face